EP0215876A1 - Pharmaceutical preparations or blood fluidification - Google Patents

Pharmaceutical preparations or blood fluidification

Info

Publication number
EP0215876A1
EP0215876A1 EP86901898A EP86901898A EP0215876A1 EP 0215876 A1 EP0215876 A1 EP 0215876A1 EP 86901898 A EP86901898 A EP 86901898A EP 86901898 A EP86901898 A EP 86901898A EP 0215876 A1 EP0215876 A1 EP 0215876A1
Authority
EP
European Patent Office
Prior art keywords
atrox
venom
combination
bothrops
venoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86901898A
Other languages
German (de)
French (fr)
Inventor
Pascal Berdal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0215876A1 publication Critical patent/EP0215876A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Réalisation de médicaments développant notamment une activité fluidifiante sanguine et se définissant par l'association d'au moins deux constituants choisis dans un groupe différent parmi les groupes suivants: les anti-aggrégants plaquettaires et(ou) les anticoagulants; les sérums et(ou) les anticorps antitissus; les substances antérieurement connues en tant que substances procoagulantes.Production of drugs developing in particular a blood-thinning activity and being defined by the association of at least two constituents chosen from a different group from the following groups: platelet anti-aggregants and (or) anticoagulants; sera and / or anti-tissue antibodies; substances previously known as procoagulant substances.

Description

TITRE :préparations pharmaceutiques fluidifiant le sang: Dans le but d'obtenir des produits développant notamment une activité pharmacologique antithrombosante plus complète grâce à l'association de produits ayant des sites d'action complémentaires ou différents, la présente innovation consiste à associer dans le même médicament au moins deux constituants choisis dans un groupe différent parmi les groupes suivants: les anticoagulants et (ou) les antiaggregants plaquettaires; les serums et (ou) anticorps antitissus;les venins et(ou) les toxines;les extraits tissulaires;les substances antérieurement connues en tant qu' agents procoagulants. TITLE: pharmaceutical preparations which thin the blood: With the aim of obtaining products developing in particular a more complete anti-thrombotic pharmacological activity thanks to the association of products having complementary or different sites of action, the present innovation consists in combining in the same medicament at least two constituents chosen from a different group from the following groups: anticoagulants and (or) platelet antiaggregants; serum and / or anti-tissue antibodies; venoms and / or toxins; tissue extracts; substances previously known as procoagulant agents.
Citons â titre d'exemples non limitatifs: -dans le groupe des antiaggregants plaquettaires :l'acide acétylsalicylique -dans le groupe des anticoagulants:l'héparineAs non-limiting examples, let us cite: -in the group of platelet antiaggregants: acetylsalicylic acid -in the group of anticoagulants: heparin
-dans le groupe des serums et (où) des anticorps antitissus:les serums et (ou) les anticorps antiplaquettes sanguines-in the group of sera and (where) anti-tissue antibodies: sera and (or) antibodies against blood platelets
-dans le groupe des venins et (ou) des toxines:les venins de élaps corallinus, naja tripudians, naja nigricollis,vipera aspis, vipéra bitis,vipera daboia,vipera torva, crotalus horridus, lachesis mutus, lachesis alternatus,bothrops atrox atrox, scorpio europeus, scorpio palmatus,prionurus australis, apis mellifica, apium virus,vespa crabo,vespa bombo, latrodectus mactans;aisi que les extraits (par exemple:les fractions protéiques) des venins et toxines et (ou) les antisérums correspondants.-in the group of venoms and (or) toxins: the venoms of élaps corallinus, naja tripudians, naja nigricollis, vipera aspis, vipéra bitis, vipera daboia, vipera torva, crotalus horridus, lachesis mutus, lachesis alternatus, bothrops atrox atrox, scorpio europeus, scorpio palmatus, prionurus australis, apis mellifica, apium virus, vespa crabo, vespa bombo, latrodectus mactans; as well as extracts (e.g. protein fractions) of venoms and toxins and (or) the corresponding antisera.
-dans le groupe des substances actuellement connues en tant que substances procoagulantes:la thrombine, la fibrine, le fibrinogène, les facteurs de coagulation, les phospholipides, les plaquetes, les extraits plaquettaires et autres activateurs de la coagulation. Les quelques exemples non limitatifs donnés ci-après ne font qu'illustrer l'innovation sans la limiter.Ils ne constituent que quelques exemples particuliers. Exemple I: acide acétylsalicylique (dose inférieure ou égale à un gramme par jour) venin de bothrops lanceolatus Exemple 2 : acide acétylsalicylique venin de bothrops lanceolatus sérum et (ou) anticorps antiplaquettes sanguines Les présentations de ces médicaments peuvent être solides ou liquides sous toutes les formes pharmaceutiques possibles préparées selon les méthodes connues de l'homme de l'art.Les principes actifs peuvent y être incorporés à tous les véhicules et excipients possibles employés dans les compositions pharmaceutiques.Les venins, les sérums, les anticorps, les substances procoagulantes seront utilisés à une dilution supérieure ou égale à la troisième dilution décimale. -in the group of substances currently known as procoagulant substances: thrombin, fibrin, fibrinogen, coagulation factors, phospholipids, platelets, platelet extracts and other coagulation activators. The few nonlimiting examples given below only illustrate innovation without limiting it, they are only a few specific examples. Example I: acetylsalicylic acid (dose less than or equal to one gram per day) venom of bothrops lanceolatus Example 2: acetylsalicylic acid venom of bothrops lanceolatus serum and (or) antibodies against blood platelets The presentations of these drugs can be solid or liquid under all Possible pharmaceutical forms prepared according to methods known to those skilled in the art. The active principles can be incorporated into all possible vehicles and excipients used in pharmaceutical compositions. Venoms, sera, antibodies, procoagulant substances will be used at a dilution greater than or equal to the third decimal dilution.

Claims

REVENDICATIONS I-Médicament destiné à fluidifier le sang et(uo) à développer une activité antiinflammatoire et (ou) antalgique, caractérisé en ce qu'il est constitué par une association d'au moins deux constituants choisisdans un groupe différent parmi les groupes suivants:les antiaggregants plaquettaires et (ou) les anticoagulants, les serums et (ou) les anticorps antitissus et (ou) les extraits tissulaires, les venins,les substances antérieurement connues comme agents procoagulants.CLAIMS I-Medication intended to thin the blood and (uo) to develop an anti-inflammatory and (or) analgesic activity, characterized in that it is constituted by a combination of at least two constituents chosen from a different group from the following groups: platelet antiaggregants and / or anticoagulants, serums and / or anti-tissue antibodies and / or tissue extracts, venoms, substances previously known as procoagulant agents.
2-Médicament selon la revendication I caractérisé en ce qu'il contient un antiaggrégant plaquettaire (tel que par exemple 1' acide acétylsalicylique) et (ou) un anticoagulant (tel que par exemple l'héparine), associé (s) à un ou plusieurs venins (s) (tel (s) crue le venin de bothrops atrox atrox ou bothrops lanceolatus, raja nigricollis, lachesis mutus, lâchesis alternatus,crotalus horridus,crotalus cascavella,vipera aspis, apis mellifica,vespa crabo,vespa bombo,naja tripudians, lachesis neuwidii,vipera daboia, vipera torva, latrodectus mactans,elaps corallinus) et (ou) aux extraits et fractions des venins et (ou) aux antisérums contre les venins et (ou) leurs fractions. 3-Médicament selon la revendication I caractérisé par l'association d'un antiaggrégant plaquettaire tel que l'acide acétylsalicylique avec le venin de bothrops lanceolatus.2-medicament according to claim I characterized in that it contains an antiplatelet agent (such as for example 1 acetylsalicylic acid) and (or) an anticoagulant (such as for example heparin), associated (s) with one or several venoms (such as raw) the venom of bothrops atrox atrox or bothrops lanceolatus, raja nigricollis, lachesis mutus, lâchesis alternatus, crotalus horridus, crotalus cascavella, vipera aspis, apis mellifica, vespa crabo, vespa bombo, naja trip , lachesis neuwidii, vipera daboia, vipera torva, latrodectus mactans, elaps corallinus) and / or extracts and fractions of venoms and (or) antisera against venoms and (or) their fractions. 3-A drug according to claim I characterized by the combination of an antiplatelet agent such as acetylsalicylic acid with the venom of bothrops lanceolatus.
4-Médicament selon la revendication I caractérisé par l'association d'un antiaggrégant plaquettaire tel que l'acide acétylsalicylique et (ou) un anticoagulant tel que l'héparine avec le venin de bothrops atrox atrox et le sérum et (ou) les anticorps anti-plaquettes sanguines.4-A drug according to claim I characterized by the combination of an antiplatelet agent such as acetylsalicylic acid and (or) an anticoagulant such as heparin with the venom of bothrops atrox atrox and serum and (or) antibodies anti-platelets.
5-Médicament selon la revendicarion I caractérisé par l'association d'un antiaggrégant plaquettaire et (ou) un anticoagulant 6-Médicament selon la revendication I caractérisé par l'association d'au moins un venin tel que le venin de bothrops atrox atrox et le sérum et(ou) les anticorps antiplaquettes sanguines. 7-Médicament selon la revendication I caractérisé en ce qu'il comprend une ou plusieurs substance (s) choisie (s) dans le groupe des substances connues antérieurement comme agents procoagulants telle (s) que par exemple:la fibrine, le fibrinogène, la thrombine, les facteurs de coagulation, les plaquettes et leurs traits, le collagène, les phospholipides, les inhibiteurs de la fibrinolyse.5-Drug according to claim I characterized by the combination of an antiplatelet agent and / or an anticoagulant 6-medicament according to claim I characterized by the combination of at least one venom such as the venom of bothrops atrox atrox and the serum and (or) antibodies to blood platelets. 7-medicament according to claim I characterized in that it comprises one or more substance (s) chosen (s) from the group of substances previously known as procoagulant agents such as (s) such as for example: fibrin, fibrinogen, thrombin, coagulation factors, platelets and their traits, collagen, phospholipids, fibrinolysis inhibitors.
8-Composition pharmaceutique caractérisée en ce qu'elle contient une quantité efficace du médicament selon l'une quelconque des revendications précédentes en association avec un véhicule pharmaceutiσuement acceptable. 8-Pharmaceutical composition characterized in that it contains an effective amount of the medicament according to any one of the preceding claims in association with a pharmaceutically acceptable vehicle.
EP86901898A 1985-03-18 1986-03-17 Pharmaceutical preparations or blood fluidification Withdrawn EP0215876A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8503965 1985-03-18
FR8503965A FR2578745B1 (en) 1985-03-18 1985-03-18 BLOOD FLUIDIFYING PHARMACEUTICAL PREPARATIONS

Publications (1)

Publication Number Publication Date
EP0215876A1 true EP0215876A1 (en) 1987-04-01

Family

ID=9317296

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86901898A Withdrawn EP0215876A1 (en) 1985-03-18 1986-03-17 Pharmaceutical preparations or blood fluidification

Country Status (4)

Country Link
EP (1) EP0215876A1 (en)
AU (1) AU5625786A (en)
FR (1) FR2578745B1 (en)
WO (1) WO1986005399A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4140981B2 (en) * 1994-12-26 2008-08-27 東菱薬品工業株式会社 Anti-restenosis and arteriosclerosis drug
JP3742675B2 (en) * 1995-06-28 2006-02-08 東菱薬品工業株式会社 Prophylactic and therapeutic agents for ischemia-reperfusion injury
IL123001A (en) * 1998-01-20 1998-12-06 Shulov Inst For Venom Research Analgesic fraction from snake venom and pharmaceutical compositions containing it
US7985428B2 (en) * 2004-08-16 2011-07-26 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Method and composition for modulation of systemic inflammatory responses syndrome (SIRS)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6256M (en) * 1967-01-26 1968-08-19
FR2222083B1 (en) * 1973-03-22 1976-05-14 Fontaine Michel
FR2487201B2 (en) * 1980-03-24 1985-07-05 Pasteur Institut LYMPHOCYTAIC PREPARATION APPLICABLE IN HUMAN THERAPEUTICS, PROCESS FOR OBTAINING AND APPLICATIONS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8605399A1 *

Also Published As

Publication number Publication date
AU5625786A (en) 1986-10-13
FR2578745A1 (en) 1986-09-19
WO1986005399A1 (en) 1986-09-25
FR2578745B1 (en) 1989-05-12

Similar Documents

Publication Publication Date Title
Mueller et al. History of drugs for thrombotic disease. Discovery, development, and directions for the future.
CA1330299C (en) Composition of anticoagulants
Tu Overview of snake venom chemistry
Pérez et al. Natural protease inhibitors to hemorrhagins in snake venoms and their potential use in medicine
AU2008203028B2 (en) Pharmaceutically stable hemostatic compositions
EP0115974B1 (en) Highly active collagenolytic preparation and pharmaceutical compositions containing it
Porges Snake venoms, their biochemistry and mode of action
FR2591485A1 (en) STABILIZED COMPOSITIONS CONTAINING THE PLASMINOGEN ACTIVATOR OF HUMAN TISSUE
EP0719791B1 (en) Medicaments for the treatment of restenosis and arterial sclerosis
Marsh et al. The Gaboon viper, Bitis gabonica: hemorrhagic, metabolic, cardiovascular and clinical effects of the venom
FR2555050A1 (en) PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THE PREPARATION OF PHOSPHATIDYLSERINE COMPOSITIONS FOR USE IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITHOUT EFFECTS ON BLOOD COAGULATION
FR2442241A2 (en) NOVEL ESTER COMPOUNDS OF MURAMYL-PEPTIDE, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, IN PARTICULAR IN THE FORM OF LIPOSOMES
Rosenfeld et al. Coagulant, proteolytic, and hemolytic properties of some snake venoms
EP0215876A1 (en) Pharmaceutical preparations or blood fluidification
CA1317878C (en) Method and therapeutic compositions for the treatment of bleeding disorders
Baggai et al. Inhibitory studies of Tamarindus indica seed extract and fractions on hematological activities of Bitis arietans venom
CN101400255B (en) Composition for treating bacterial, virus, fungal disease, inflammation and ache
Sani et al. Inhibition of snake venom enzymes and antivenom adjuvant effects of Azadirachta indica A. Juss.(Meliaceae) leaf extracts
JPS62255430A (en) Treatment for mammalian vas disease
Mackay et al. The venom of the boomslang (Dispholidus typus): in vivo and in vitro studies
Peichoto et al. Systemic pathological alterations caused by Philodryas patagoniensis colubrid snake venom in rats
FR2522266A1 (en) PROCESS FOR THE PREPARATION OF A FIBRINOLYTICALLY ACTIVE AGENT AND AGENT OBTAINED
FR2570278A1 (en) COMPOSITIONS AND METHOD FOR PROTECTING T LYMPHOCYTES AGAINST THE ETIOLOGICAL AGENT OF LYMPHADENOPATHIES AND ACQUIRED IMMUNODEPRESSION SYNDROME
Menarim et al. Bone marrow mononuclear cells for joint therapy: The role of macrophages in inflammation resolution and tissue repair
EP0185584B1 (en) Utilization of the heteropolyanion (nasb9w21086)18- for the manufacture of a pharmaceutical composition for the treatment of aids and analogous syndromes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19861219